정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 793 | Withdrawn | Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk | COVID-19 | Drug: Hydroxychloroquine Sulfate | Not Applicable | Texas Cardiac Arrhythmia Research Foundation | OTHER | 0 | All | 18 Months ~ 85 Years | |
| 792 | Recruiting | Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm | Covid-19 | Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension | Phase 2 | Auxilio Mutuo Cancer Center | OTHER | 20 | All | 18 Years | San Juan City Hospital / Puerto Rico Medical Center, San Juan, Puerto Rico Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico |
| 791 | Completed | Prophylactic Ivermectin in COVID-19 Contacts | COVID | Drug: Ivermectin Tablets | Phase 3 | Zagazig University | OTHER_GOV | 340 | All | 16 Years ~ 70 Years | Zagazig University, Zagazig, Sharkia, Egypt |
| 790 | Completed | Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan | SARS (Severe Acute Respiratory Syndrome) | Drug: Ivermectin / Iota-Carrageenan | Phase 2 | Maria de los Angeles Peral de Bruno | OTHER_GOV | 300 | All | 18 Years ~ 60 Years | SI.PRO.SA, Ministerio de Salud Publica, Tucuman, Argentina |
| 789 | Recruiting | Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC) | Covid19 | Drug: Ivermectin Other: Placebo |
Phase 3 | Ministry of Public Health, Argentina | OTHER_GOV | 750 | All | 18 Years ~ 60 Years | SI.PRO.SA, Ministerio de Salud Publica, Tucuman, Argentina |
| 788 | Withdrawn | PROphylaxis for paTiEnts at Risk of COVID-19 infecTion | COVID-19 | Drug: Hydroxychloroquine Sulfate 200 MG | Phase 3 | Cambridge University Hospitals NHS Foundation Trust, University of Cambridge | OTHER | 0 | All | 18 Years | |
| 787 | Recruiting | PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V | Covid19 | Drug: Niclosamide Drug: Placebo |
Phase 3 | Cambridge University Hospitals NHS Foundation Trust, LifeArc, Kidney Research UK (KRUK), UNION therapeutics, Addenbrookes Charitable Trust | OTHER | 1500 | All | 18 Years | Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridshire, United Kingdom |